| Managed Access Programs for LDK378, Ceritinib (NCT05100134) | Novartis Pharmaceuticals | |
| HUD: PIP Joint Implant (NCT02434913) | The Hawkins Foundation | |
| Expanded Access for CC-4047 (NCT03723096) | Celgene | |
| Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis (NCT02148146) | University of California, San Diego | |
| Expanded Access for Anti-IL8 (NCT05210894) | Bristol-Myers Squibb | |
| Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered (NCT05518838) | Oblato, Inc. | |
| MLN8237 for a Subject With Adenocarcinoma of the Prostate (NCT03005262) | The University of Texas Health Science Center at San Antonio | |
| Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (NCT03068650) | Celldex Therapeutics | |
| Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma (NCT04452994) | Janssen Research & Development, LLC | |
| Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) (NCT03493165) | The University of Texas Health Science Center at San Antonio | |
| Expanded Access Program for Revumenib (NCT05918913) | Syndax Pharmaceuticals | |
| Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) (NCT01279798) | NovaRx Corporation | |
| The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms (NCT03810287) | Yale University | |
| Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma (NCT05503550) | Janssen Research & Development, LLC | |
| Medical Access Program for Patritumab Deruxtecan (NCT06099639) | Daiichi Sankyo | |
| Expanded Access Program of Surufatinib (NCT04814732) | Hutchmed | |
| Expanded Access for KHK2455 (NCT04321694) | Kyowa Kirin, Inc. | |
| Single Patient Expanded Access Protocol: Metabolic Boost (NCT02021266) | Talaris Therapeutics Inc. | |
| Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease (NCT01949766) | University of Pittsburgh | |
| Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib (NCT03386071) | Jonsson Comprehensive Cancer Center | |
| Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis (NCT04514952) | Hope Biosciences Research Foundation | |
| Treatment Use of 3,4-Diaminopyridine (NCT01765140) | Vern C. Juel, M.D. | |
| Global Managed Access Program Cohort for Ligelizumab in CSU (NCT04903613) | Novartis Pharmaceuticals | |
| Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders (NCT02567175) | Prasanna K Kapavarapu | |
| A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 (NCT01196208) | Seagen Inc. | |
| Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children (NCT02925520) | Cook Children's Health Care System | |
| Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults (NCT03945903) | Janssen Research & Development, LLC | |
| Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma (NCT02449135) | Fuda Cancer Hospital, Guangzhou | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer (NCT04507919) | Novartis Pharmaceuticals | |
| Expanded Access for PSV Personalized Oncolytic Viruses (NCT03529539) | EpicentRx, Inc. | |
| ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) (NCT04453839) | APR Applied Pharma Research s.a. | |
| Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) (NCT05161598) | Janssen Research & Development, LLC | |
| Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) (NCT04360486) | U.S. Army Medical Research and Development Command | |
| A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment (NCT00210665) | Janssen Research & Development, LLC | |
| A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2) (NCT06069934) | Prilenia | |
| Expanded Access to ANG1005 for Individual Patients (NCT02755987) | Angiochem Inc | |
| Expanded Access Using Allogeneic Bone-marrow Derived Human Mesenchymal Stem Cells (Allo-hMSC) for a Individual Parkinson's Disease Subject (NCT06798064) | Mya Schiess | |
| Pulmonary Vein Isolation Outcomes With Fish Oils (NCT00841451) | St. Luke's-Roosevelt Hospital Center | |
| Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) (NCT00419367) | Merck Sharp & Dohme LLC | |
| An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus (NCT02433314) | Supernus Pharmaceuticals, Inc. | |
| Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis (NCT05897294) | TFF Pharmaceuticals, Inc. | |
| Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer (NCT05002465) | Dana Mathews | |
| Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma (NCT02082691) | Devalingam Mahalingam | |
| Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (NCT01784562) | Bayer | |
| Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion (NCT03206931) | Bayer | |
| Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (NCT02271139) | Genentech, Inc. | |
| A Belatacept Compassionate Use Study for Patients With a Kidney Transplant (NCT00719225) | Bristol-Myers Squibb | |
| Expanded Access to Epcoritamab (NCT05692050) | AbbVie | |
| Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS (NCT05281484) | Clene Nanomedicine | |
| Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery (NCT00832273) | Vital Therapies, Inc. | |
| 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly) (NCT04854369) | Tulane University | |
| Expanded Access for CC-2001 (NCT03723083) | Celgene | |
| Ocular Fluorophotometry for Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU). (NCT01908985) | EyeTechCare | |
| Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome (NCT02968953) | Jerry Vockley, MD, PhD | |
| Expanded Access for Dasatinib (NCT00454753) | Bristol-Myers Squibb | |
| Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma (NCT02297529) | Amgen | |
| Expanded Access to Convalescent Plasma for Treatment of COVID-19 (NCT04472572) | Hackensack Meridian Health | |
| Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study (NCT04381091) | Santhera Pharmaceuticals | |
| An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) (NCT03114228) | Novartis Pharmaceuticals | |
| An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NCT03523338) | Aragon Pharmaceuticals, Inc. | |
| Compassionate Use of the Incraft® AAA Stent Graft System (NCT01776450) | Cordis US Corp. | |
| Special Access for the Use of Voclosporin for Kidney Transplantation (NCT01236287) | Weill Medical College of Cornell University | |
| Expanded Access for Relatlimab (NCT05170659) | Bristol-Myers Squibb | |
| Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC (NCT07399015) | Endevica Bio | |
| Expanded Access to Rovalpituzumab Tesirine (NCT03503890) | AbbVie | |
| Compassionate Use of REGN-COV2 for the Treatment of COVID-19 (NCT04617535) | Regeneron Pharmaceuticals | |
| Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection (NCT03834376) | Janssen Research & Development, LLC | |
| Emergency/Compassionate Use - Membranous VSD Occluder (NCT00583505) | Abbott Medical Devices | |
| Domperidone Expanded Access Treatment Program (NCT04996134) | Wake Forest University Health Sciences | |
| US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT05627466) | Gilead Sciences | |
| Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma (NCT02147951) | Amgen | |
| Expanded Access of Sotorasib (NCT04667234) | Amgen | |
| Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor (NCT05225259) | Eli Lilly and Company | |
| Expanded Access Treatment Protocol CA204-143 (NCT02368301) | Bristol-Myers Squibb | |
| Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older (NCT05541289) | Ocugen | |
| Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma (NCT02541643) | Sundar Jagannath | |
| Study of Cannabidiol for Drug-Resistant Epilepsies (NCT03014440) | Eric Marsh, MD | |
| Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies (NCT03317366) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 (NCT03593499) | Biogen | |
| Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase (NCT02197650) | ERYtech Pharma | |
| Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease (NCT04540861) | Novartis Pharmaceuticals | |
| Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC (NCT02824094) | Pfizer | |
| A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients (NCT00799539) | Janssen-Ortho Inc., Canada | |
| An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer (NCT02784158) | Ariad Pharmaceuticals | |
| Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer (NCT03906357) | Incyte Corporation | |
| Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure (NCT01206504) | MacroGenics | |
| 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) (NCT02174679) | Jonsson Comprehensive Cancer Center | |
| A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation (NCT00149981) | Novartis Pharmaceuticals | |
| Use of the Pressure Right Device After Laparoscopic Surgery (NCT01317082) | Therapeutics: 101 Inc. | |
| Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use) (NCT02084121) | Talaris Therapeutics Inc. | |
| Convalescent Plasma for the Treatment of Patients With COVID-19 (NCT04372368) | University of Colorado, Denver | |
| Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA) (NCT05086094) | Biohaven Pharmaceuticals, Inc. | |
| Expanded Access to VAL-083 (NCT03138629) | Kintara Therapeutics, Inc. | |
| Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy (NCT04029896) | Hope Biosciences Research Foundation | |
| Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma (NCT02186249) | Bristol-Myers Squibb | |
| Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) (NCT04346277) | Implicit Bioscience | |
| Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer (NCT00701168) | Leo W. Jenkins Cancer Center | |